Expert: Humanized IgG2 monoclonal antibody targeting APRIL (A Proliferation-Inducing Ligand). Reduces production of galactose-deficient IgA1 (Gd-IgA1), the pathogenic driver of IgA nephropathy, by inhibiting APRIL-mediated B cell and plasma cell signaling.
Everyday: Blocks a protein called APRIL that fuels the immune system to make defective antibodies (IgA). In IgA kidney disease, these defective antibodies clog the kidney filters — blocking APRIL stops them from being made.
Targets: []